A COMPARATIVE CHARACTERISTICS OF TREATMENT RESULTS OF PATIENS WITH BENIGN PROSTATIC HYPERPLASIA IN COMBINATION WITH HYPOGONADISM
- 作者: Kamalov A.A.1, Vasilevskiy R.P2, Okhobotov D.A1, Neplokhov E.A3
-
隶属关系:
- Lomonosov Moscow State University
- Municipal Polyclinic №134
- Tomsk OGAUZ I.D. Evtushenko Regional Perinatal Center
- 期: 编号 4 (2019)
- 页面: 58-61
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312228
- DOI: https://doi.org/10.18565/urology.2019.4.58-61
- ID: 312228
如何引用文章
详细
全文:
作者简介
A. Kamalov
Lomonosov Moscow State University
Email: armais.kamalov@rambler.ru
Academician of the RAS, MD, professor, Director of Medical Scientific and Educational Center, Head of the Department of Urology and Andrology, Faculty of Fundamental Medicine Moscow, Russia
R. Vasilevskiy
Municipal Polyclinic №134
Email: urolog-rv@yandex.ru
urologist, Head of the Department of Urology of MP №134 Moscow, Russia
D. Okhobotov
Lomonosov Moscow State University
Email: 14032007m@gmail.com
Ph.D., urologist and senior researcher at the Scientific Department “Urology and Andrology” of Medical Research and Educational Center Moscow, Russia
E. Neplokhov
Tomsk OGAUZ I.D. Evtushenko Regional Perinatal Center
Email: md.neplohov@mail.ru
Ph.D., urologist at the Department of ART Tomsk, Russia
参考
- Ефремов Е.А., Красняк С. С. Возможные риски при терапии тестостероном. Экспериментальная и клиническая урология. 2017;1:90-97.
- Мамедов М.Н., Шарвадзе Г.Г., Поддубская Е.А., Салек Б.Г., Мехтиевз Т.В., Мехтиев С.Х. Междисциплинированный подход к проблемам мужского здоровья с целью улучшения качества и продолжительности жизни. Профилактическая Медицина. 2011; 14(5):30-35.
- Baillargeon J., Urban R.J., Kuo Y.F., et al. Screening and Monitoring in Men Prescribed Testosterone Therapy in the U.S., 2001-2010. Public Health Rep 2015;130(2):143-152.
- Basaria S. Male hypogonadism. Lancet 2014;383(924):1250-1263. Doi: 10.1016/ S0140-6736(13)61126-5. Epub 2013 Oct 10.
- Herati A.S., Kohn T.P., Butler P.R., Lipshultz L. Effects of Testosterone on Benign and Malignant Conditions of the Prostate. Curr Sex Health Rep. 2017;9,(2):65- 73. doi: 10.1007/s11930-017-0104-7. Epub 2017 Apr 26.
- Jarvis T.R., ChughtaiB., Kaplan S.A. Testosterone and benign prostatic hyperplasia. Asian J Androl. 2015;17(2):212-216. doi: 10.4103/1008-682X.140966.
- Ko I.G., Hwang L., Jin J.J., Kim S.H., Han J.H., Jeon J.W., Cho S.T. Add-on Therapy With the а-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats. Int Neurourol J. 2018;22(1):20-29. doi: 10.5213/inj.1836064.032. Epub 2018 Mar 31.
- Lee J.H., Kim Y., Park Y.W., Lee D.G. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men. J Sex Med. 2014; 11(5): 1309-1315. doi: 10.1111/jsm.12489.
- Mulhall J.P., Trost L.W., Brannigan R.E., Kurtz E.G., Redmon J.B., Chiles K.A., Lightner D.J., Miner M.M., MuradM.H., Nelson C.J., Platz. E.A., Ramanathan L.V., LewisR.W. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: 10.1016/j.juro.2018.03.115. Epub 2018 Mar 28.
- Shim J.S., Kim J.H., Yoon Y.S., Choi H., Park J.Y., Bae J.H. Serum Testosterone Levels Are Negatively Correlated with International Prostate Symptom Score and Transitional Prostate Volume. Low Urin Tract Symptoms. 2018;10(2):143-147. doi: 10.1111/luts.12150.